Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 5/20 | 0.41 |
| ▸ | MLYCD | O95822 | 3/20 | 0.41 |
| ▸ | PDE4A | P27815 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6120083 | 0.82 | PDE4A (0.44) | PDE4DPDE4APDE4BPDE4CALOX15 | |
| SCHEMBL19214125 | 0.81 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4CALOX15 | |
| SCHEMBL17711306 | 0.81 | ALDH1A1 (0.49) | MLYCDACHEHTT | |
| SCHEMBL6120909 | 0.78 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4CALOX15 | |
| SCHEMBL2297062 | 0.78 | NOTUM (0.51) | PDE4DPDE4APDE4BPDE4CALOX15 | |
| SCHEMBL17709917 | 0.76 | CES1 (0.41) | MLYCDCES1ACHE | |
| SCHEMBL6120781 | 0.74 | PDE4D (0.50) | PDE4DPDE4APDE4BPDE4CALOX15 | |
| SCHEMBL17711396 | 0.73 | MAPT (0.54) | CES1ACHEHTTSMN1; SMN2 | |
| SCHEMBL26323147 | 0.73 | CES1 (0.45) | MLYCDCES1ACHE | |
| SCHEMBL8848226 | 0.73 | ALOX15 (0.58) | MLYCDALOX15GFERADAM17CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3354651-B1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3212643-B1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-20 | — | — | EP | disclosed |
| US-10150762-B2 | Trifluoromethyl alcohols as modulators of RORγt | JANSSEN PHARMACEUTICA, NV (BE) | 2018-12-11 | — | — | US | disclosed |
| EP-3354651-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2018-08-01 | — | — | EP | disclosed |
| CN-107827841-A | Trifluoromethyl alcohol as Ror γ t conditioning agents | 詹森药业有限公司 | 2018-03-23 | — | — | CN | disclosed |
| US-9850236-B2 | Trifluoromethyl alcohols as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-26 | — | — | US | disclosed |
| US-9850236-B2 | Trifluoromethyl alcohols as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-26 | — | — | US | disclosed |
| US-9850236-B2 | Trifluoromethyl alcohols as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-26 | — | — | US | disclosed |
| US-20170327492-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-16 | — | — | US | disclosed |
| US-20170327492-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-16 | — | — | US | disclosed |
| US-20170327492-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-16 | — | — | US | disclosed |
| EP-3212643-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | Janssen Pharmaceutica, N.V. (BE) | 2017-09-06 | — | — | EP | disclosed |
| CN-107108599-A | Trifluoromethanols as Ror gamma t modulators | 詹森药业有限公司 | 2017-08-29 | — | — | CN | disclosed |
| WO-2016069974-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122336-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122336-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122336-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (US) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122336-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | RORC, RORA, RORB | PDE4D 1383/4885MLYCD 4800/4885PDE4A 774/4885 |
| US-20170327492-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | RORA, RORC, RORB | PDE4D 1849/4885MLYCD 3139/4885PDE4A 1703/4885 |
| US-10150762-B2 | Trifluoromethyl alcohols as modulators of RORγt | RORC, RORA, RORB | PDE4D 2426/4885MLYCD 3167/4885PDE4A 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.